Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Cut to $27.00 by Analysts at The Goldman Sachs Group
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective trimmed by The Goldman Sachs Group from $39.00 to $27.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also issued reports on DAWN. JPMorgan Chase & Co. dropped their […]
Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price objective trimmed by The Goldman Sachs Group from $39.00 to $27.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also issued reports on DAWN. JPMorgan Chase & Co. dropped their […]
